The potential of emerging therapeutics for epithelioid sarcoma

References

• Enzinger F. Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970;26(5):1029–1041.
   Google Scholar
• Fisher C. Epithelioid sarcoma of enzinger. Adv Anat Pathol. 2006;13(3):114–121.
   Google Scholar
• Rakheja D, Wilson KS, Meehan J, et al. “Proximal-type” and classic epithelioid sarcomas represent a clinicopathologic continuum: case report. Pediatr Dev Pathol. 2005;8(1):105–114.
   Google Scholar
• Prat J, Woodruff JM, Marcove RC. Epithelioid sarcoma: an analysis of 22 cases indicating the prognostic significance of vascular invasion and regional lymph node metastasis. Cancer. 1978;41(4):1472–1487.
   Google Scholar
• Orrock JM, Abbott JJ, Gibson LE, et al. INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics. Am J Dermatopathol. 2009;31(2):152–156.
   Google Scholar
• Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33(4):542–550.
   Google Scholar
• Kohashi K, Izumi T, Oda Y, et al. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: A useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol. 2009;40(3):349–355.
   Google Scholar
• Jawad MU, Extein J, Min ES, et al. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the seer database. Clin Orthop Relat Res. 2009;467(11):2939–2948.
   Google Scholar
• Baratti D, Pennacchioli E, Casali PG, et al. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2007;14(12):3542–3551.
   Google Scholar
• Levy A, Le Pechoux C, Terrier P, et al. Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment. Ann Surg Oncol. 2014;21(1):269–276.
   Google Scholar
• Chase DR, Enzinger FM. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985;9(4):241–263.
   Google Scholar
• Jones RL, Constantinidou A, Olmos D, et al. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012;35(4):351–357.
   Google Scholar
• Miettinen M, Fanburg-Smith JC, Virolainen M, et al. Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum Pathol. 1999;30(8):934–942.
   Google Scholar
• Lin L, Hicks D, Xu B, et al. Expression profile and molecular genetic regulation of Cyclin D1 expression in epithelioid sarcoma. Mod Pathol. 2005;18(5):705–709.
   Google Scholar
• Tan SH, Ong BH. Spindle cell variant of epithelioid sarcoma: an easily misdiagnosed tumour. Australas J Dermatol. 2001;42(2):139–141.
   Google Scholar
• Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: A clinicopathologic and immunohistochemical analysis of 106 cases from the french sarcoma group. Am J Clin Pathol. 2009;131(2):222–227.
   Google Scholar
• Guillou L, Wadden C, Coindre JM, et al. “Proximal-type” epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol. 1997;21(2):130–146.
   Google Scholar
• Frezza A, Botta L, Pasquali S, et al. An epidemiological insight into epithelioid sarcoma (ES): the open issue of distal-type (DES) versus proximal-type (PES). Eur Soc Med Oncol. 2017.
   Google Scholar
• Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000;7(3):218–225.
   Google Scholar
• Wolf PS, Flum DR, Tanas MR, et al. Epithelioid sarcoma: the university of washington experience. Am J Surg. 2008;196(3):407–412.
   Google Scholar
• Shimm DS, Suit HD. Radiation therapy of epithelioid sarcoma. Cancer. 1983;52(6):1022–1025.
   Google Scholar
• Maduekwe UN, Hornicek FJ, Springfield DS, et al. Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas. Ann Surg Oncol. 2009;16(5):1356–1363.
   Google Scholar
• Andreou D, Boldt H, Werner M, et al. Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread–results of a large prospective trial. Ann Oncol. 2013;24(5):1400–1405.
   Google Scholar
• Piovesan C, Dileo P, Puma E, et al. Proximal-type epithelioid sarcomas: a retrospective analysis of 31 patients. Connective Tissue Oncology Society 15th Annual Meeting. Miami, USA. 2009. page 73 (abstract 39396).
   Google Scholar
• Pink D, Richter S, Gerdes S, et al. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis. Oncology. 2014;87(2):95–103.
   Google Scholar
• Frezza A, Asano N, Jones J, et al. Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: results of a retrospective multi-institutional case series. In: American Society of Clinical Oncology. Chicago, USA. J Clin Oncol. 2017;35(15_suppl):11065.
   Google Scholar
• Tariq Z, Ghose A, Bawany MZ, et al. A case report of complete remission of pulmonary metastases from epithelioid sarcoma to navelbine chemotherapy. Am J Ther. 2012;19(2):e95–97.
   Google Scholar
• Anderson SE, Keohan ML, D’Adamo DR, et al. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma. 2006;2006(15947).
   Google Scholar
• Touati N, Schoffski P, Litiere S, et al. EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy. Eur Soc Med Oncol. 2017.
   Google Scholar
• Schuetze SM, Bolejack V, Choy E, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017;123(1):90–97.
   Google Scholar
• Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6(24).
   Google Scholar
• Kalpana GV, Marmon S, Wang W, et al. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 1994;266(5193):2002–2006.
   Google Scholar
• Wang X, Haswell JR, Roberts CW. Molecular pathways. SWi/SNF (baf) complexes are frequently mutated in cancer–mechanisms and potential therapeutic insights. Clin Cancer Res. 2014;20(1):21–27.
   Google Scholar
• Brenca M, Rossi S, Lorenzetto E, et al. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ. Mol Cancer Ther. 2013;12(6):1060–1072.
   Google Scholar
• Sullivan LM, Folpe AL, Pawel BR, et al. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod Pathol. 2013;26(3):385–392.
   Google Scholar
• Papp G, Changchien YC, Peterfia B, et al. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma. Mod Pathol. 2013;26(3):393–403.
   Google Scholar
• Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343–349.
   Google Scholar
• Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316–328.
   Google Scholar
• Alimova I, Birks DK, Harris PS, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol. 2013;15(2):149–160.
   Google Scholar
• Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922–7927.
   Google Scholar
• Gounder M, Stacchiotti S, Schoffski O, et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (nct02601950). Available from: https://clinicaltrials.gov/ct2/show/NCT02601950
   Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.
   Google Scholar
• Darr J, Klochendler A, Isaac S, et al. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/SNF5-mediated tumorigenesis. Oncogene. 2014;33(23):3024–3032.
   Google Scholar
• Imura Y, Yasui H, Outani H, et al. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer. 2014;13(185):1–18.
   Google Scholar
• O’Reilly KE, Rojo F, She QB, et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res. 2006;66(3):1500–1508.
   Google Scholar
• Eroglu Z, Tawbi HA, Hu J, et al. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015;112(10):1644–1651.
   Google Scholar
• Sibilia M, Kroismayr R, Lichtenberger BM, et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007;75(9):770–787.
   Google Scholar
• Dobashi Y, Takei N, Suzuki S, et al. Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol. 2004;17(12):1497–1505.
   Google Scholar
• Xie X, Ghadimi MP, Young ED, et al. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011;17(18):5901–5912.
   Google Scholar
• Cascio MJ, O’Donnell RJ, Horvai AE. Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare. Mod Pathol. 2010;23(4):574–580.
   Google Scholar